| |
 |
 |
| Company Name |
Novartis (Taiwan) Co., Ltd. |
| Protocol Number |
CLDT600ATW03 |
| Title of Study |
A prospective, open-label, nonrandomized, multi-center, surveillance registry study to evaluate the safety, tolerability and effectiveness of telbivudine in treatment of chronic hepatitis B patients in Taiwan. |
| Primary Objective |
The primary objective is to evaluate the long-term safety of telbivudine in treatment of chronic hepatitis B patients for current clinical use. |
| Number of Sites |
30 |
| Period of Study |
from 2009-09-01 to 2012-02-28 |
| Number of Patients |
100 |
| IRB Approval Date |
2-Sep-2009 |
| Publication Plan / Date |
30-Apr-2012 |
|
|
|
|
